Novo Nordisk announced the discontinuation of Levemir (insulin detemir [rDNA origin] injection) FlexPen on September 30, 2014. After this date, and once the wholesaler’s inventory is exhausted, no additional product will be available.
This action is related to the launch of Levemir FlexTouch from June 2014. Levemir FlexTouch is the first prefilled insulin delivery device with a no push-button extension and allows insulin to be administered by pressing the low dose force button. It contains 300 units of insulin detemir (long-acting) that doses in 1-unit increments, from 1–80 units. It is compatible with both NovoFine and NovoTwist needles.
Levemir is a man-made insulin used to control high blood sugar in adults and children with diabetes. Patients currently using Levemir FlexPen will require a new prescription on file for FlexTouch. Patients do not need to return Levemir FlexPen if they have it in their possession.
For more information call (800) 727-6500 or visit LevemirPro.com.
This article originally appeared on MPR